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Abstract
Background: B7 Costimulatory signal is essential to trigger T-cell activation upon the recognition
of tumor antigens. This study examined the expression of B7-1 (CD80) and B7-2 (CD86)
costimulatory molecules along with HLA-DR and the presence of infiltrating lymphocytes and
dendritic cells to assess their significance in patients with nasopharyngeal carcinoma (NPC).
Methods: Expression of CD80, CD86, HLA-DR, S-100 protein and the presence of infiltrating
lymphocytes and follicular dendritic reticulum cells were immunohistochemically examined on the
paraffin-embedded tissue blocks from newly diagnosed NPC patients (n = 50). The results were
correlated with clinical outcome of patients.
Results: CD80 and CD86 were each expressed in 10 of 50 cases in which they co-expressed in 9
cases. Univariate analysis revealed that patients with CD80/CD86 expression had significantly
better overall survival than those without it (P = 0.017), but after adjustment for stage, nodal status,
and treatment, the expression of CD80/CD86 did not significantly correlate with overall survival.
Expression of HLA-DR and the presence of infiltrating lymphocytes and dendritic cells did not
appear to have impact on the survival of patients.
Conclusion: Expression of CD80 and CD86 costimulatory molecules appears to be a marker of
better survival in patient with NPC.
Background
Nasopharyngeal carcinoma (NPC) is a neoplasm with
high incidence in Southeast Asia, the Mediterranean
basin, and North Africa. Early-stage NPC is usually treated
with radiotherapy alone, and combination of chemother-
apy is effective in the more advanced-stages of NPC [1-4].
Identification of a pathobiological correlate of clinical
behavior of NPC represents a challenge. The development
of such a test may improve the outcome of treatment as
high-risk patients could benefit from early intervention
and aggressive treatment.
B7 Costimulatory molecules are membrane-bound mole-
cules which play a decisive role in the activation of T cells.
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This costimulatory pathway involves the interaction of
two distinct B7 molecules, B7-1 (CD80) and B7-2
(CD86), which are transmembrane glycoprotein mem-
bers of the Ig superfamily [5-7] expressed on antigen-pre-
senting cells with their T cell counter receptors CD28 and
CTLA-4 [8]. Interaction of B7:CD28 has been shown to
provide a critical signal for T cell activation, while the
absence of this signal results in T cell anergy [8,9]. It is
speculated that T cell anergy as the result of a paucity of B7
costimulatory molecules, which may permit the immune
evasion of the cancer, is one of the mechanisms responsi-
ble for the poor immunogenicity of tumor cells. Experi-
mental evidence has confirmed the expression of B7
costimulatory molecules in tumor cells of NPC [10,11], it
is therefore interesting to determine whether B7 costimu-
latory molecules are factors influencing the survival out-
come of patients.
In the present study, we analyzed 50 NPC tissue samples
to investigate the presence of CD80 and CD86 costimula-
tory molecules and establish their clinical significance in
NPC. The significance of infiltrating cells (lymphocytic
and dendritic cells) and HLA-DR expression in tumor cells
were also examined in parallel and correlated with sur-
vival in patients with NPC.
Methods
Patient selection and tissue specimens
Paraffin embedded tissue blocks (5–7 μm) from biopsies
of newly diagnosed NPC patients between January 2001
and December 2002 were retrieved from the Department
of Pathology, Changhua Christian Hospital, Taiwan (n =
50) with informed consent according to guidelines of the
Changhua Christian Hospital Institution Review Board.
All patients were staged according to the 1997 American
Joint Committee on Cancer tumor-node-metastasis stag-
ing systems [12]. The pathological stage and nodal status
were obtained from the primary pathology reports. Slides
from tumors were reviewed by two pathologists to define
the histological grading. The survival data were either
obtained from the cancer registry of Changhua Christian
Hospital or collected from the patients' attending physi-
cians. 42 of the 50 patients received concurrent chemora-
diotherapy consisting of cisplatin and fluorouracil. Five
patients (T1-2 N0) along with three patients with T stage
of 3–4 refused chemotherapy were treated with radiation
alone. The median follow-up period was 56 months
(range, 1–73 months).
Immunohistochemical staining
Blocks were sectioned and put on poly-1-lysine coated
slides. After deparaffinized, the section was treated with
3% H2O2 in methanol. The sections were then hydrated
through gradient alcohol and PBS. Slides were placed in
10 mM citrate buffer and heated for 20 minutes in a 700-
W microwave oven at 100°C in PBS. Slides from each case
were exposed to 1:200 dilution of anti-CD80 monoclonal
antibody (Santa Cruz Biotechnology, USA) and 1:100
dilution of anti-CD86 polyclonal antibody (Immunotech,
Marseille, France) for 30 minutes at room temperature
followed by incubation with a PicTure Polymer Kits for 20
minutes (Zymed, South San Francisco, USA). The sections
were thoroughly washed with PBS between steps. The sites
of peroxidase were visualized with 3,3'-diaminobenzidine
tetrahydrochloride. Hematoxylin was used for counter-
staining. The percentage of immunoreactivity in the
tumor cells was scored as 0 to +2. Immunoreactivity in
<10% of tumor cells was considered as aberrant expres-
sion (-), 10–50% (+1), and >50% (+2). All fields in the
sections were examined. Investigator-bias was avoided by
two investigators independently scoring coded sections.
Furthermore, CD80 and CD86 positive samples were
repeated to ensure that no false positive results occurred
in the experiment.
Same steps and scoring systems were carried out with the
following monoclonal and polyclonal antibodies to
address the expression of HLA-DR and the presence of
infiltrating lymphocytes and dendritic cells: anti-CD45R0,
anti-CD20, and anti-Follicular Dendritic Reticulum Cells
(all from Dakocytomation, Denmark); anti-HLA Class II
(DR) and anti-S-100 (both from Novocastra Laboratories,
UK).
Statistical analysis
Survival curves in accordance with various potential prog-
nostic indicators were produced. Survival was defined as
the time between date of diagnosis and date of death.
Immunohistochemical staining for (A) CD 80- and (B) CD80  (+1) in undifferentiated carcinoma of the nasopharynx  (×400); (C) CD 86- in non-keratinizing squamous cell and (D)  CD86 (+2) in undifferentiated carcinoma of the nasopharynx  (×400) Figure 1
Immunohistochemical staining for (A) CD 80- and (B) CD80 
(+1) in undifferentiated carcinoma of the nasopharynx 
(×400); (C) CD 86- in non-keratinizing squamous cell and (D) 
CD86 (+2) in undifferentiated carcinoma of the nasopharynx 
(×400).BMC Cancer 2007, 7:88 http://www.biomedcentral.com/1471-2407/7/88
Page 3 of 7
(page number not for citation purposes)
Patients still alive at the end of the study were censored at
the date of last follow-up. Sections scored as +1 and +2
were identified as positive staining to decrease the
number of variables for statistical purpose. Survival rate
was computed using standard Kaplan-Meier methods,
and the difference in survival curves was analyzed by the
log-rank test. Independent prognostic factors were ana-
lyzed by the Cox proportional hazards regression model.
Variables in the model included T stage, nodal (N) stage,
and treatment (radiotherapy or concurrent chemoradio-
therapy). A P value of less than 0.05 was considered to
indicate statistical significance.
Results and discussion
CD80/CD86 expression
Regardless of stage and histological type, CD80 and CD86
were each expressed in 10 of 50 cases in which they co-
expressed in 9 cases. Expression of CD80 and CD86 were
classified as a group to reduce the number of prognostic
variables as 9 patients had overlapping expression. Posi-
tive membrane and occasional cytoplasmic staining of
CD80/CD86 was observed in 11 of the 50 patients (Figure
1, Table 1). CD80/CD86 expression was not noticed in
normal nasopharyngeal mucosal epithelia. Abnormal
nasopharyngeal epithelia were hardly present in our biop-
sies.
Uni-and multivariate analyses for prognostic factors
The Univariate analysis revealed that there was a signifi-
cant association between expression of either CD80 or
CD86 and clinical outcome in terms of survival (P =
0.017) (Table 2). The Kaplan-Meier survival curves of the
50 NPC patients were plotted into 2 groups according to
immunostaining results with either CD80/CD86 positive
or negative (Figure 2). Due to the limited number of
patients, in the multivariate analysis which incorporated
independent prognostic factors of T stage, N stage, and
treatment (concurrent chemoradiotherapy vs. radiother-
apy alone), we found that CD80/86 expression was not
significant with regard to survival (Table 3). No associa-
tion was observed between CD80/86 expression and the
infiltration of T-cells and dendritic cells (Table 4).
Table 1: Characteristics of 50 patients with nasopharyngeal carcinoma
Characteristics Overall CD80/86(+)
No. % No. %
Age, years
Range 38–83 38–78
Median 50 46
Mean 53 50
Sex
Male 42 84 10 91
F e m a l e 81 61 9
Pathology (WHO classification)
Type I -- --
Type II 35 70 6 55
Type III 15 30 5 45
T Stage (1997 AJCC)
T1 or T2 32 64 9 82
T3 or T4 18 36 2 18
N Stage (1997AJCC)
N0 or N1 24 48 6 55
N2 17 34 3 27
N 3 91 82 1 8
Overall Stage (1997 AJCC)
I5 1 0 3 2 7
II 10 20 3 27
III 13 26 2 18
IV 22 44 3 27
Treatment
Radiotherapy alone 8 16 2 18
Concurrent Chemoradiotherapy 42 84 9 82
Status
Death 16 32 0 0
Alive 34 68 11 100
Abbreviations: WHO, World Health Organization; AJCC, American Joint Committee on Cancer; FDRC, Follicular Dendritic Reticulum CellsBMC Cancer 2007, 7:88 http://www.biomedcentral.com/1471-2407/7/88
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T, B, and dendritic cell infiltration and HLA-DR expression 
in NPC tissue sections
Subpopulations of infiltrating lymphocytes in NPC were
identified using anti-T (CD45R0) and anti-B (CD20) cell
antibodies. Follicular dendritic reticulum cells, S-100 pro-
tein which marks infiltrating dendritic cells, along with
tumor HLA-DR (Figure 3) expression were also identified
in this study. However, none were statistically significant
for survival (Table 2).
Conclusion
Studies have described the presence of B7 costimulatory
molecules in tumor cells of NPC, and the corresponding
counter-receptor, CD28, in lymphoid cells, implying
some communication between T cells and carcinoma cells
in the microenvironment of NPC [10,11]. These data sug-
gest certain level of immune response directed at the NPC
tumor cells with the presence of B7 costimulatory mole-
cules in tumor cells of NPC and the vast number of infil-
trating T cells. This phenomenon might explain why in
the majority of NPC patients, the large prevalence of T
cells in the neoplastic tissue does not have any prognostic
Table 2: Univariate analysis for overall survival of patients with nasopharyngeal carcinoma
Kaplan-Meier Survival Rate
Censored
Total Dead N % P-value
Overall 50 16 34 68.0
T Negative 7 3 4 57.1 0.543
Positive 43 13 30 69.8
B Negative 9 4 5 55.6 0.253
Positive 41 12 29 70.7
FDC Negative 20 8 12 60.0 0.286
Positive 30 8 22 73.3
CD80* Negative 40 16 24 60.0 0.025
Positive 10 0 10 100.0
CD86* Negative 40 16 24 60.0 0.025
Positive 10 0 10 100.0
CD80/86* Negative 39 16 23 59.0 0.017
Positive 11 0 11 100.0
HLA1DR Negative 15 7 8 53.3 0.167
Positive 35 9 26 74.3
S100 Negative 20 7 13 65.0 0.654
Positive 30 9 21 70.0
P-value by Log-rank test
Follow-up time: from diagnosis date till death/2-15-2007
Kaplan-Meier survival curves based on expression of CD80/ CD86 for patients with nasopharyngeal carcinoma Figure 2
Kaplan-Meier survival curves based on expression of CD80/
CD86 for patients with nasopharyngeal carcinoma.BMC Cancer 2007, 7:88 http://www.biomedcentral.com/1471-2407/7/88
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significance. The presence of B7 costimulatory molecules
is essential for the activation of T cells.
Our experimental evidence supports the finding that in a
subset of NPC patients, tumor cells indeed express B7 cos-
timulatory molecules. CD80 and CD86 were each
expressed in 10 of 50 of our NPC cases in which they co-
expressed in 9 cases. Due to the limited number of NPC
cases, statistical conclusions which correlate the expres-
sion of CD80/86 with survival can not be drawn in the
multivariate analysis in this study. Additional studies with
larger number of patients are needed to confirm this find-
ing.
However, this study demonstrated the presence of B7 cos-
timulatory molecules in the neoplastic tissue of NPC and
their possible prognostic importance. It is the first to show
a significant association between expression of CD80/
CD86 and a favorable outcome in patients with NPC by
univariate analysis.
With a relatively small group of patients, our data sug-
gested that neither expression of HLA-DR, the presence of
infiltrating dendritic cells (follicular and S-100(+) inter-
digitating), nor the prevalence of lymphocytes in the neo-
plastic tissue had any prognostic significance for survival
in patients with NPC. However, we can not rule out that
with large number of patients, the prognostic factors
might have been significant on the basis of this report.
The absence or low level expression of B7 costimulatory
molecules by malignant cells is thought to represent one
mechanism by which they escape immunosurveillance.
Recently, CD80 expression has been demonstrated to be
closely associated with decreased tumorigenicity in oral
squamous carcinoma, suggesting that inadequate CD80
expression during early oral squamous cell carcinoma for-
mation may contribute to the escape of tumors from the
immune system [13]. The fact that 9 of the 11 (82%)
CD80/86 positive patients were in T stage of 1–2 provide
indirect evidence that expression of CD80/86 may serve as
Table 4: Association of CD80/86 expression and infiltration of T-cell/Dendritic cells in nasopharyngeal carcinoma
CD80/86
Negative (n = 39) Positive (n = 11) Total (n = 50) Φ P-value
N%N%N%
T Negative 6 15.4 1 9.1 7 14.0 0.075 1.000
Positive 33 84.6 10 90.9 43 86.0
FDC Negative 13 33.3 7 63.6 20 40.0 -0.256 0.090
Positive 26 66.7 4 36.4 30 60.0
S-100 Negative 16 41.0 4 36.4 20 40.0 0.039 1.000
Positive 23 59.0 7 63.6 30 60.0
P-value by Fisher's Exact Test
Φ: Phi correlation coefficient
Table 3: Multivariate analysis of clinicopathologic factors for overall survival of patients with nasopharyngeal carcinoma
Total Dead % HR 95% C.I. for HR P-value
CD80/86 Negative 39 16 41.0 1.000 0.968
Positive 11 0 0.0 0.000 0.000 - 6.853E+282
T Stage 1 or 2 32 7 21.9 1.000 0.050
3 or 4 18 9 50.0 2.892 1.001 - 8.353
N Stage 0 or 1 24 5 20.8 1.000 0.065
2 or 3 26 11 42.3 2.830 0.938 - 8.539
Treatment RT 8 1 12.5 1.000 0.193
CCRT 42 15 35.7 3.979 0.497 - 31.870
HR: Hazard RatioBMC Cancer 2007, 7:88 http://www.biomedcentral.com/1471-2407/7/88
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a marker for decreased tumorigenicity during early devel-
opment of NPC.
The question of whether expression of B7 costimulatory
molecules represent enhanced immunity against tumor
has important implications with regard to the prognosis
and treatment of NPC. The demonstration in this study
which addresses the presence of B7 costimulatory mole-
cules in the neoplastic tissue of NPC and their possible
role in the prognosis of this disease is important. It should
be noted that B7 expression could be widely determined
on routinely processed, paraffin-embedded tissues for
prognostic evaluation in NPC cases, whereas the quantifi-
cation of plasma EBV DNA [14] can only be reliably per-
formed for the purpose of clinical evaluation in
sophisticated centers. Finally, integration of multiple
markers and tools through use of statistical modeling
should improve our ability to identify high-risk patients
who may benefit from refined treatment strategies.
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